SAN FRANCISCO, Calif. — VeriSIM Life today announced it has been awarded a Phase II Small Business Technology Transfer (STTR) grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to advance its proprietary BIOiSIM® mechanistic AI platform for the discovery of novel therapeutics for stimulant use disorder.
SAN FRANCISCO, Calif. — VeriSIM Life today announced it has been awarded a Phase II Small Business Technology Transfer (STTR) grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to advance its proprietary BIOiSIM® mechanistic AI platform for the discovery of novel therapeutics for stimulant use disorder.
San Francisco, CA – June 25, 2025 — VeriSIM Life, a leading innovator in AI-powered drug development, today announced that it has been awarded “Machine Learning Platform of the Year” in the 2025 AI Breakthrough Awards. This honor recognizes VeriSIM’s flagship platform, BIOiSIM®, for its unparalleled ability to transform drug discovery through the power of predictive modeling and translational intelligence.
San Francisco, CA – June 25, 2025 — VeriSIM Life, a leading innovator in AI-powered drug development, today announced that it has been awarded “Machine Learning Platform of the Year” in the 2025 AI Breakthrough Awards. This honor recognizes VeriSIM’s flagship platform, BIOiSIM®, for its unparalleled ability to transform drug discovery through the power of predictive modeling and translational intelligence.
San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures.
San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures.
.png)
.png)
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-ligand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
